UPDATE: Cowen Starts Trillium Therapeutics (TRIL) at Outperform

Cowen initiated coverage on Trillium Therapeutics (NASDAQ: TRIL) with an Outperform rating. Analyst Boris Peaker sees potential in the company's novel SIRPaFc molecule.

"Trillium Therapeutics is an early-stage biotechnology company whose lead asset, SIRPaFc is a novel antibody-like checkpoint inhibitor. Anti CD47 therapies have a wide range of application in oncology because CD47 is ubiquitously expressed on all cancers. CD47 is also one of the first validated checkpoint targets present in the myeloid arm of the immune system. We believe that investor interest will continue to grow in this nascent space and Trillium's SIRPaFc may emerge as the best-in-class anti-CD47 therapy," said Peaker.

For an analyst ratings summary and ratings history on Trillium Therapeutics click here. For more ratings news on Trillium Therapeutics click here.

Shares of Trillium Therapeutics closed at $24.21 yesterday.

You May Also Be Interested In

• Cellebrite (CLBT) PT Lowered to $15 at TD Cowen
• Birkenstock Holding plc (BIRK) PT Raised to $44 at Morgan Stanley
• Ascendis Pharma (ASND) PT Raised to $333 at Jefferies